Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Omicron Subvariant BA.2: What We Know Now
Known as BA.2, the new Omicron subvariant is now circulating at low levels in the US. What can you tell your patients? Here's what we know, now.
The COVID-19 Omicron subvariant, known as BA.2, is circulating in the US at "low levels," according to the Centers for Disease Control and Prevention. About half the states have confirmed its presence, with about 127 cases identified as of today.
But in Denmark the subvariant represents more than 80% of cases seen. Case numbers are creeping up in the UK, and BA.2 is becoming the dominant Omicron strain in the Philippines, Nepal, Qatar, and India.
While all data remain preliminary, they point to the potential for an infection that is even more transmissable than the original Omicron strain, BA.1, but not any more infectious. Following is a topline look at what we know now.
Recent Videos
Related Content
